Nature Communications (Jul 2020)
A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing
- Wen-Wei Zhang,
- Subir Karmakar,
- Sreenivas Gannavaram,
- Ranadhir Dey,
- Patrick Lypaczewski,
- Nevien Ismail,
- Abid Siddiqui,
- Vahan Simonyan,
- Fabiano Oliveira,
- Iliano V. Coutinho-Abreu,
- Thiago DeSouza-Vieira,
- Claudio Meneses,
- James Oristian,
- Tiago D. Serafim,
- Abu Musa,
- Risa Nakamura,
- Noushin Saljoughian,
- Greta Volpedo,
- Monika Satoskar,
- Sanika Satoskar,
- Pradeep K. Dagur,
- J. Philip McCoy,
- Shaden Kamhawi,
- Jesus G. Valenzuela,
- Shinjiro Hamano,
- Abhay R. Satoskar,
- Greg Matlashewski,
- Hira L. Nakhasi
Affiliations
- Wen-Wei Zhang
- Department of Microbiology and Immunology, McGill University
- Subir Karmakar
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Sreenivas Gannavaram
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Ranadhir Dey
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Patrick Lypaczewski
- Department of Microbiology and Immunology, McGill University
- Nevien Ismail
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Abid Siddiqui
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Vahan Simonyan
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Fabiano Oliveira
- Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Iliano V. Coutinho-Abreu
- Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Thiago DeSouza-Vieira
- Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Claudio Meneses
- Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- James Oristian
- Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Tiago D. Serafim
- Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Abu Musa
- Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan and Nagasaki University Graduate School of Biomedical Sciences Doctoral Leadership Program
- Risa Nakamura
- Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan and Nagasaki University Graduate School of Biomedical Sciences Doctoral Leadership Program
- Noushin Saljoughian
- Department of Pathology and Microbiology, Ohio State University
- Greta Volpedo
- Department of Pathology and Microbiology, Ohio State University
- Monika Satoskar
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Sanika Satoskar
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Pradeep K. Dagur
- National Institute of Heart, Lung and Blood Institute, NIH
- J. Philip McCoy
- National Institute of Heart, Lung and Blood Institute, NIH
- Shaden Kamhawi
- Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Jesus G. Valenzuela
- Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Shinjiro Hamano
- Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan and Nagasaki University Graduate School of Biomedical Sciences Doctoral Leadership Program
- Abhay R. Satoskar
- Department of Pathology and Microbiology, Ohio State University
- Greg Matlashewski
- Department of Microbiology and Immunology, McGill University
- Hira L. Nakhasi
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- DOI
- https://doi.org/10.1038/s41467-020-17154-z
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
Here, the authors engineer an attenuated knock-out Leishmania (LmCen −/−) vaccine that is safe in immunocompromised mice and induces an immune response and protection similar to leishmanization with wild-type Leishmania. Since LmCen −/− is antibiotic resistant marker free, it is a candidate for clinical development.
